The company also entered into two separate financing agreements totaling $41.5 million with Innovatus Life Sciences Lending Fund, East West Bank, and Aspire Capital.
The company will use the proceeds in part to develop its Next Generation Profiling offering to analyze cancer genomes, transcriptomes, and proteomes with clinical outcome data.
The firm will use the agreement to access alternative non-dilutive means of financing of its growth plans.
The French diagnostics firm said it will use the funding to support its merger and acquisition strategy.
The company issued more than 1.8 million shares of its common stock to several of its trade creditors to erase debt that it owed them, Precipio said in an SEC document.
The company may use the proceeds of the loans to help fund the $7.2 billion acquisition of Patheon. The loan facility follows a $1.5 billion senior notes offering by Thermo Fisher last week.
The company plans to use the net proceeds to partially fund the $7.2 billion acquisition of pharmaceutical contract development and manufacturing firm Patheon.
GeneNews has signed a binding agreement with multinational private equity firm Milost Global for up to $10 million in equity and debt financing.
Singulex plans to use the investment to continue to develop its single-molecule counting technology.
The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.